A study of 48 patients with cancer of unknown primary reported that patient-centered precision therapy guided by comprehensive genomic profiling was associated with longer overall survival than empirical chemotherapy. The analysis centers on how genomic profiling can translate an undefined cancer presentation into targeted treatment decisions, improving outcomes compared with standard empiric approaches. While the cohort is small, the work adds to evidence that broad genomic characterization may be clinically actionable even when the primary tumor site is not identified. For oncology teams, the finding supports continued investment in genomic testing workflows and emphasizes the need to connect profiling results to practical therapeutic assignment within real-world care pathways.